Abnova (Taiwan) Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 4/6
Abnova (Taiwan) has been growing earnings at an average annual rate of 26.3%, while the Life Sciences industry saw earnings growing at 20.8% annually. Revenues have been declining at an average rate of 2.3% per year. Abnova (Taiwan)'s return on equity is 5.1%, and it has net margins of 18.1%.
Key information
26.3%
Earnings growth rate
26.3%
EPS growth rate
| Life Sciences Industry Growth | 5.5% |
| Revenue growth rate | -2.3% |
| Return on equity | 5.1% |
| Net Margin | 18.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Abnova (Taiwan) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 365 | 66 | 90 | 36 |
| 31 Mar 24 | 372 | 60 | 91 | 36 |
| 31 Dec 23 | 382 | 44 | 88 | 38 |
| 30 Sep 23 | 396 | 45 | 90 | 41 |
| 30 Jun 23 | 404 | 61 | 87 | 44 |
| 31 Mar 23 | 408 | 68 | 85 | 47 |
| 31 Dec 22 | 412 | 75 | 88 | 49 |
| 30 Sep 22 | 401 | 62 | 88 | 50 |
| 30 Jun 22 | 415 | 48 | 91 | 51 |
| 31 Mar 22 | 436 | 36 | 95 | 51 |
| 31 Dec 21 | 451 | 28 | 100 | 53 |
| 30 Sep 21 | 474 | 40 | 100 | 53 |
| 30 Jun 21 | 492 | 41 | 104 | 54 |
| 31 Mar 21 | 471 | 39 | 104 | 53 |
| 31 Dec 20 | 456 | 37 | 105 | 51 |
| 30 Sep 20 | 440 | 29 | 114 | 50 |
| 30 Jun 20 | 405 | 14 | 120 | 49 |
| 31 Mar 20 | 405 | 13 | 126 | 51 |
| 31 Dec 19 | 414 | 3 | 128 | 55 |
| 30 Sep 19 | 407 | 16 | 121 | 56 |
| 30 Jun 19 | 415 | 26 | 115 | 57 |
| 31 Mar 19 | 425 | 36 | 113 | 58 |
| 31 Dec 18 | 426 | 46 | 113 | 57 |
| 30 Sep 18 | 441 | 44 | 115 | 55 |
| 30 Jun 18 | 457 | 51 | 116 | 55 |
| 31 Mar 18 | 465 | 55 | 116 | 54 |
| 31 Dec 17 | 475 | 59 | 113 | 53 |
| 30 Sep 17 | 467 | 63 | 108 | 53 |
| 30 Jun 17 | 453 | 55 | 108 | 52 |
| 31 Mar 17 | 442 | 51 | 110 | 50 |
| 31 Dec 16 | 440 | 54 | 110 | 49 |
| 30 Sep 16 | 449 | 46 | 115 | 48 |
| 30 Jun 16 | 446 | 47 | 116 | 48 |
| 31 Mar 16 | 458 | 59 | 113 | 48 |
| 31 Dec 15 | 451 | 45 | 114 | 49 |
| 30 Sep 15 | 449 | 58 | 113 | 48 |
| 30 Jun 15 | 453 | 66 | 114 | 45 |
| 31 Mar 15 | 441 | 52 | 115 | 44 |
| 31 Dec 14 | 438 | 66 | 119 | 43 |
| 30 Sep 14 | 435 | 55 | 115 | 46 |
| 30 Jun 14 | 437 | 54 | 113 | 45 |
| 31 Mar 14 | 443 | 62 | 116 | 42 |
| 31 Dec 13 | 464 | 73 | 116 | 41 |
Quality Earnings: 4133 has high quality earnings.
Growing Profit Margin: 4133's current net profit margins (18.1%) are higher than last year (15.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4133's earnings have grown significantly by 26.3% per year over the past 5 years.
Accelerating Growth: 4133's earnings growth over the past year (7.3%) is below its 5-year average (26.3% per year).
Earnings vs Industry: 4133 earnings growth over the past year (7.3%) exceeded the Life Sciences industry -5.2%.
Return on Equity
High ROE: 4133's Return on Equity (5.1%) is considered low.